Evotec SE announced that it has joined the NURTuRE-AKI consortium for establishing a patient cohort for acute kidney injury (AKI), NURTure-AKI. This initiative will enable Evotec to identify key mechanisms that trigger AKI and to support the discovery of highly innovative treatments for AKI patients based on a molecular understanding of the disease. NURTuRE-AK I focuses on adult and pediatric cardiac surgery patients who are at high risk of developing AKI as well as patients undergoing AKI-to-CKD progression.
The longitudinal study design includes biological sampling and clinical data collection at multiple time points for each patient. Blood, urine and research biopsy samples will be subjected to omics analyses, forming the most comprehensive patient cohort for AKI and AKI-to-C KD worldwide. NURTuRE- AKI will be integral to Evotec's Molecular Patient Database (E.MPD), a repository of high-quality multi-omics data (PanOmics) and detailed clinical records.
This new addition will further enhance Evotec's understanding of human diseases and expand its capabilities in precision medicine, drug discovery and development programs. NURTuRE-akI will unlock the identification of novel therapeutic targets and biomarkers based on comprehensive molecular and clinical patient data. This will accelerate the development of targeted therapies for a disease with a high unmet medical need, providing immense benefits for millions of patients worldwide. NURTuRE -AKI is a unique resource for the kidney disease community, accelerating discovery of new treatments and diagnostic approaches through secure provision of a rich resource of biological samples and data.
The initial cohorts comprised 3,000 individuals with CKD and 740 with idiopathic nephrotic syndrome (INS). With the development of NURTuRE-AKi, this resource will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI.
